Aptamer-gold nanozyme based competitive lateral flow assay for rapid detection of CA125 in human serum

Biosens Bioelectron. 2020 Oct 1:165:112368. doi: 10.1016/j.bios.2020.112368. Epub 2020 Jun 9.

Abstract

For several decades, point-of-care technology (POCT) has proven its potential regarding swift and cost-efficient detection of analytes. Lateral flow assay is a highly popular POC technology that needs improvisation to increase its sensitivity, cost effectiveness and quantification so that it becomes more user friendly and affordable technology. In this context, the present study has investigated the use of aptamers and nanozymes together for the first time in developing an Aptamer-nanozyme lateral flow assay (ALFA). The present study uses a specific aptamer for CA125 as capture reagent and peroxidase mimetic gold nanoparticles as label for detection of CA125 in human serum through developed competitive ALFA. The assay was specific and has a limit of detection of 3.71 U/mL. The ALFA test was in house validated for its precision, recovery and showed a significant correlation with established CA125 chemiluminiscent ELISA with P-value<0.0001. In summary, this assay quantitatively detects an analyte by using an aptamer and peroxidase mimetic gold nanoparticles that ensures circumventing the use of antibodies and incorporating enzyme mimetic activity in assay systems.

Keywords: Aptamer; CA125; Lateral flow assay; Nanozyme.

MeSH terms

  • Aptamers, Nucleotide*
  • Biosensing Techniques*
  • Gold
  • Humans
  • Limit of Detection
  • Metal Nanoparticles*

Substances

  • Aptamers, Nucleotide
  • Gold